For those not there. Here is At the Limits 2017

If you don't live near London, fear not, because the meeting will no doubt be filmed, 

Indeed last year it was "live streamed" and the events went online.
You can watch it, if you follow the links here

However, because the organizers i.e. ProfG and Prof Carroll had got enough sponsors, the event could not be hosted on the Lancet website. Hopefully, the Profs will learn from their mistakes. 

Thre next year we can get the link and so you can watch from the comfort of your armchair. However, if you are there you can join in the discussion.

However, have you got 2 free days? is the weekend after all, because I have found the links

Day 1. (8 hours & forty Three minutes) (CLICK HERE)

Day 2 ( 6 hours Thirty-seven minutes) (CLICK HERE)

Here is the programme (Below).

I did a 30minute talk in 15minutes so it was very rushed. 
I think I learned to Breath through my ears for that:-). 

However, my learned opponent was not prepared for the my British Style of Debating. I argued from an extreme view standpoint and time the jokes perfectly. However, I did a shocking job on the questions...not frank enough. Anyway have a  wtach if you are interested

Monday 20th November
From 08:00
Registration and Coffee
Introduction and Welcome from the Chairs
Cellular immunology and its relevance to MS
B-cells subsets and their role in MS
Professor Amit Bar-Or
Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, Philadelphia, PA USA

NK-cells as a therapeutic target in MS
Professor Dr Roland Martin
University of Zurich, Zurich, Switzerland

Coffee Break
Role of T-regs in the treatment of MS
Dr Joanne Jones
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

B-cell induced autoimmunity
Dr Vijay K. Kuchroo
Brigham and Women's Hospital, Boston, MA, USA

Progressive Multiple Sclerosis
Therapeutic lag in progressive MS trials
Professor Maria Pia Sormani
Department of Health Sciences, University of Genoa, Italy

How to define secondary progressive MS
Dr Tomas Kalincik
Melbourne Brain Centre, Royal Melbourne Hospital, Melbourne, Australia

Coffee Break
Energetics and its role in progressive MS
Dr Don Mahad
Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, Edinburgh, UK

The expanding MS lesion as a treatment target in MS
Dr Daniel Reich
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA

Debate: "To B or not T-B: that is the question"; the key pathogenic cell in MS is a B-cell and is independent of antigen presentation to T-cells
Professor David Baker
Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK

Prof. Dr. med. Heinz Wiendl
Department of Neurology Universität Münster, Albert-Schweitzer-Campus 1 Münster, Germany
Scientific sessions close
Tuesday 21st November
Progressive Multiple Sclerosis contd.
Motor-sensory prognostic paradox in MS
Professor Gavin Giovannoni
Barts and The London School of Medicine and Dentistry, London, UK

Disease improvement in progressive MS trials
Dr Bruce Cree
Department of Neurology, UCSF School of Medicine, San Francisco, CA, USA
Coffee Break

Epidemiology of Multiple Sclerosis
The case for EBV vaccination to prevent MS
Professor Alberto Ascherio
Department of Nutrition, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Cambridge, MA, USA

Vitamin D as a disease-modifying treatment for MS
Dr Joost Smolders
Canisius Wilhelmina Ziekenhuis Nijmegen, The Netherlands

Epidemiology of Multiple Sclerosis contd.
Lifestyle & environmental factors and their interactions with multiple sclerosis risk genes
Professor Tomas Olsson
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

TNF-alpha and what it tells us about MS
Professor Lars Fugger
The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

Sex hormones in MS
Dr Riley Bove
UCSF School of Medicine, Department of Neurology, UCSF, San Francisco, CA, USA
Closing comments from Chairs